TY  - JOUR
N1  - Copyright of this article belongs to Tazlore and Francis Group.
ID  - open1073
UR  - http://informahealthcare.com/doi/abs/10.1517/14728222.12.8.969%20
IS  - 8
A1  - Mir, Manzoor A
A1  - Agrewala, J N
Y1  - 2008/08//
N2  - This study shows that anti-CD80 immunotherapy may have a potent role in treating CD80-bearing cancer cells.
PB  - Taylor and francis group
JF  - Expert opinion on therapeutic targets
VL  - 12
SN  - 1744-7631
TI  - Signaling through CD80: an approach for treating lymphomas.
SP  - 969
AV  - none
EP  - 79
ER  -